RTP Mobile Logo
Lung Cancer Update, Issue 3, 2012
Released January 2013

Featuring interviews with Drs Julie R Brahmer, Roy S Herbst, Jeffrey Bradley and David P Carbone. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Lung cancer is the leading cause of cancer mortality in the United States for both men and women, resulting in more deaths than breast, prostate, colon and pancreatic cancer combined. However, progress in the screening, prevention and treatment of this disease has been limited. In 2012 it is estimated that 226,160 new cases will be diagnosed and 160,340 deaths will occur in the United States. Traditional chemotherapy, surgery and radiation therapy have had a modest effect on long-term outcomes. With the advent of biologic agents in lung cancer, the field has seen recent improvements in disease-free and overall survival in select patient populations. Published results from ongoing and completed studies lead to the continual emergence of novel therapeutic strategies and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing clinician must be well informed of these advances. Featuring information on the latest research developments along with expert perspectives, this CME program is designed to assist medical oncologists and radiation oncologists with the formulation of up-to-date clinical strategies for the care of patients with lung cancer.

    LEARNING OBJECTIVES
    • Describe emerging data on the efficacy and safety of tumor immunotherapy directed at the PD-1/PD-L1 pathway in lung cancer, and consider this information when counseling patients regarding clinical trial options.
    • Identify distinct subtypes of adenocarcinoma of the lung — including those with EGFR mutations, EML4-ALK gene fusions, MET amplifications and other recently identified driver mutations — and the investigational and approved treatment strategies available to patients expressing these biomarkers.
    • Use clinical characteristics and tumor histology to develop personalized treatment algorithms for patients with early-stage and advanced non-small cell lung cancer (NSCLC).
    • Develop an evidence-based treatment approach to the selection of induction and maintenance biologic therapy and/or chemotherapy in patients with advanced NSCLC.
    • Review emerging research evidence with the use of the irreversible EGFR tyrosine kinase inhibitor afatinib alone or in combination with an EGFR monoclonal antibody for patients with advanced EGFR mutation-positive NSCLC.
    • Consider the use of high-dose radiation therapy (RT) with concurrent chemotherapy, with or without EGFR inhibitors, in addition to positron emission tomography/computed tomography (PET/CT)-guided RT in selected patients with locally advanced NSCLC.
    • Recall the scientific rationale for ongoing investigation of novel agents or therapeutic approaches in lung cancer, and counsel appropriately selected patients about study participation.
    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    This CME activity contains both audio and print components. The participant should review the CME information, listen to the audio MP3s, and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr BrahmerAdvisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Lilly USA LLC, Merck; Paid Research: ArQule Inc, MedImmune Inc; Uncompensated Research: Bristol-Myers Squibb Company. Dr HerbstAdvisory Committee: Lilly USA LLC, Pfizer Inc; Consulting Agreement: Genentech BioOncology. Dr BradleyPaid Research: Varian Medical Systems Inc. Dr CarboneConsulting Agreements: Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS
    — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This activity is supported by educational grants from Astellas, Biodesix Inc, Celgene Corporation, Daiichi Sankyo Inc, Genentech BioOncology and Lilly USA LLC.

    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: January 2013
    Expiration date: January 2014

Acknowledge and close

Listen to audio:
Lung Cancer Update, Issue 3, 2012
Released January 2013

Featuring interviews with Drs Julie R Brahmer, Roy S Herbst, Jeffrey Bradley and David P Carbone. (Text and Audio Content)

Read print: